Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
UniMixer: A Unified Architecture for Scaling Laws in Recommendation Systems
arXiv:2604.00590v2 Announce Type: replace-cross Abstract: In recent years, the scaling laws of recommendation models have attracted increasing attention, which govern the relationship between performance and parameters/FLOPs of recommenders. Currently, there are three mainstream architectures for achieving scaling in recommendation models, namely attention-based, TokenMixer-based, and factorization-machine-based methods, which exhibit fundamental differences in both design philosophy and archit
-
cs.AI, q-bio.NC updates on arXiv.org
-
EchoMark: Perceptual Acoustic Environment Transfer with Watermark-Embedded Room Impulse Response
arXiv:2511.06458v2 Announce Type: replace-cross Abstract: Acoustic Environment Matching (AEM) is the task of transferring clean audio into a target acoustic environment, enabling engaging applications such as audio dubbing and auditory immersive virtual reality (VR). Recovering similar room impulse response (RIR) directly from reverberant speech offers more accessible and flexible AEM solution. However, this capability also introduces vulnerabilities of arbitrary ``relocation" if misused by mal
EchoMark: Perceptual Acoustic Environment Transfer with Watermark-Embedded Room Impulse Response
-
cs.AI, q-bio.NC updates on arXiv.org
-
Improving Safety Alignment via Balanced Direct Preference Optimization
arXiv:2603.22829v1 Announce Type: new Abstract: With the rapid development and widespread application of Large Language Models (LLMs), their potential safety risks have attracted widespread attention. Reinforcement Learning from Human Feedback (RLHF) has been adopted to enhance the safety performance of LLMs. As a simple and effective alternative to RLHF, Direct Preference Optimization (DPO) is widely used for safety alignment. However, safety alignment still suffers from severe overfitting, wh
Improving Safety Alignment via Balanced Direct Preference Optimization
-
Omics in Hepatocellular
-
ESM1 drives cancer angiogenesis and bevacizumab resistance via trioleate synthesis
Neoplasia. 2026 May;75:101298. doi: 10.1016/j.neo.2026.101298. Epub 2026 Mar 20.ABSTRACTBACKGROUND: Hepatocellular carcinoma (HCC) exhibits high recurrence rates and limited therapeutic options. Endothelial cell-specific molecule 1 (ESM1) and angiopoietin-like 4 (ANGPTL4) are implicated in tumor progression, yet their synergistic role in HCC lipid metabolism and angiogenesis remains unexplored.METHODS: We integrated multi-omics approaches, including RNA sequencing, metabolomics, and immunoprecip
ESM1 drives cancer angiogenesis and bevacizumab resistance via trioleate synthesis
Neoplasia. 2026 May;75:101298. doi: 10.1016/j.neo.2026.101298. Epub 2026 Mar 20.
ABSTRACT
BACKGROUND: Hepatocellular carcinoma (HCC) exhibits high recurrence rates and limited therapeutic options. Endothelial cell-specific molecule 1 (ESM1) and angiopoietin-like 4 (ANGPTL4) are implicated in tumor progression, yet their synergistic role in HCC lipid metabolism and angiogenesis remains unexplored.
METHODS: We integrated multi-omics approaches, including RNA sequencing, metabolomics, and immunoprecipitation-mass spectrometry, in HCC cell lines and patient-derived xenograft models. Key experiments involved Co-IP, Western blotting, tube formation assays, and clinical tissue microarray analysis to validate the ESM1-ANGPTL4-FASN-trioleate axis.
RESULTS: ESM1 and ANGPTL4 formed a positive feedback loop, stabilizing fatty acid synthase (FASN) to promote trioleate synthesis. Trioleate activated the NF-κB/IL-17 pathway in HCC cells and upregulated CD99 in endothelial cells, driving angiogenesis. In vivo, ESM1/ANGPTL4 knockdown suppressed tumor growth, which was rescued by trioleate supplementation. Clinical data revealed elevated ESM1/ANGPTL4 expression in bevacizumab-resistant HCC, correlating with poor prognosis.
CONCLUSIONS: The ESM1-ANGPTL4-FASN-trioleate axis orchestrates metabolic reprogramming and endothelial activation, representing a promising therapeutic target. Future studies should explore combination therapies targeting this axis and overcoming bevacizumab resistance in HCC.
PMID:41864037 | PMC:PMC13019581 | DOI:10.1016/j.neo.2026.101298